Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells

By Horie Ryosuke   Nakamura Osamu   Yamagami Yoshiki   Mori Masaki   Nishimura Hideki   Fukuoka Natsuko   Yamamoto Tetsuji  

International Journal of Oncology, Vol. 48, Iss. 1, 2016-01 ,pp. : 37-44

Spandidos Publications

Access to resources Recommend Favorite

Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study

By Liu Yan   Zhang Xiaobei   Liu Jingjing   Hou Guofang   Zhang Sheng   Zhang Jin  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1275-1286

Springer Publishing Company

Access to resources Recommend Favorite

The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts

By Behrens Diana   Lykkesfeldt Anne   Fichtner Iduna  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 12, Iss. 2, 2012-02 ,pp. : 151-162

Bentham Science Publishers

Access to resources Recommend Favorite